{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}],"units":"Participants"}],"description":"Number of participants with OR based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1.\n\nCR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \\<10 mm). No new lesions.\n\nPR was defined as \\>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.","groups":[{"description":"PF-06671008 was administered as a weekly intravenous (IV) infusion in 21-day cycles at 1.5 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG000","title":"PF-06671008 1.5 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 7.5 ng/kg. PF-06671008 was administered for up to 3 cycles in this cohort.","id":"OG001","title":"PF-06671008 7.5 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 20 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG002","title":"PF-06671008 20 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 50 ng/kg. PF-06671008 was administered for up to 2 cycles in this cohort.","id":"OG003","title":"PF-06671008 50 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 100 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG004","title":"PF-06671008 100 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 200 ng/kg. PF-06671008 was administered for up to 16 cycles in this cohort.","id":"OG005","title":"PF-06671008 200 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 300 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG006","title":"PF-06671008 300 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 400 ng/kg. PF-06671008 was administered for up to 2 cycles in this cohort.","id":"OG007","title":"PF-06671008 400 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly subcutaneous (SC) injection in 21-day cycles at 200 ng/kg. PF-06671008 was administered for up to 5 cycles in this cohort.","id":"OG008","title":"PF-06671008 200 ng/kg SC"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at a priming dose of 200 ng/kg on Cycle 1 Day 1 (C1D1) and 300 ng/kg for all subsequent dosing. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG009","title":"PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV"}],"populationDescription":"This study was terminated early and Part 2 was not initiated. Data for this outcome measure was not collected.","reportingStatus":"POSTED","timeFrame":"Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months","title":"Number of Participants With Objective Response (OR) - Part 2","type":"PRIMARY"}